Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.

TitleCytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.
Publication TypeJournal Article
Year of Publication2010
AuthorsMitsani D, M Nguyen H, Kwak EJ, Silveira FP, Vadnerkar A, Pilewski J, Crespo M, Toyoda Y, Bermudez C, Clancy CJ
JournalThe Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation//J Heart Lung Transplant
Volume29
Issue9
Pagination1014 - 20
Date Published2010
ISBN Number1557-3117
Other Numbersa0q, 9102703
Keywords*Cytomegalovirus Infections/ep [Epidemiology], *Lung Transplantation/ae [Adverse Effects], *Tissue Donors, Acute Disease, Adolescent, Adult, Aged, Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal/tu [Therapeutic Use], Antibodies, Neoplasm/tu [Therapeutic Use], Antiviral Agents/tu [Therapeutic Use], Cytomegalovirus Infections/pc [Prevention & Control], Cytomegalovirus Infections/tm [Transmission], Female, Follow-Up Studies, Ganciclovir/aa [Analogs & Derivatives], Ganciclovir/tu [Therapeutic Use], Graft Rejection/pc [Prevention & Control], Heart-Lung Transplantation/ae [Adverse Effects], Humans, Immunosuppressive Agents/tu [Therapeutic Use], Male, Middle Aged, Pyrimidines/tu [Therapeutic Use], Reoperation/sn [Statistics & Numerical Data], Retrospective Studies, Survivors, Time Factors, Triazoles/tu [Therapeutic Use], Voriconazole
Abstract

BACKGROUND: Valganciclovir prophylaxis is advocated for lung transplant recipients, but its efficacy is unknown., METHODS: Retrospective review was done of 109 donor-positive/recipient-negative lung transplant patients who received alemtuzumab induction and valganciclovir for cytomegalovirus prophylaxis., RESULTS: Median duration of follow-up after transplant was 27 months. Valganciclovir dose reductions (

Notify Library Reference ID4276

Related Incidents